Adlai Nortye Ltd
ANL1.530USD
+0.010+0.66%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
169.37MMarket Cap
LossP/E TTM
More Details of Adlai Nortye Ltd Company
Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.
Adlai Nortye Ltd Info
Ticker SymbolANL
Company nameAdlai Nortye Ltd
IPO dateSep 29, 2023
CEOBirgerson (Lars Erik)
Number of employees123
Security typeDepository Receipt
Fiscal year-endSep 29
Addressc/o PO Box 309
CityGRAND CAYMAN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCayman Islands
Postal codeKY1-1104
Phone18482307430
Websitehttps://www.adlainortye.com/
Ticker SymbolANL
IPO dateSep 29, 2023
CEOBirgerson (Lars Erik)
Company Executives of Adlai Nortye Ltd
Name
Name/Position
Position
Shareholding
Change
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Victoria Elizabeth Demby
Dr. Victoria Elizabeth Demby
Senior Vice President, Global Head of Regulatory Affairs
Senior Vice President, Global Head of Regulatory Affairs
--
--
Ms. Wei (Vicky) Zhang
Ms. Wei (Vicky) Zhang
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Mr. Ming Lun (Alan) Tse
Mr. Ming Lun (Alan) Tse
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Shaorong Liu
Mr. Shaorong Liu
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Kaiyang Tang
Dr. Kaiyang Tang
Senior Vice President, Global Head of Clinical Operations
Senior Vice President, Global Head of Clinical Operations
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Victoria Elizabeth Demby
Dr. Victoria Elizabeth Demby
Senior Vice President, Global Head of Regulatory Affairs
Senior Vice President, Global Head of Regulatory Affairs
--
--
Ms. Wei (Vicky) Zhang
Ms. Wei (Vicky) Zhang
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Nov 12
Updated: Wed, Nov 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nortye International Ltd
7.47%
Nortye Talent Ltd
1.12%
Two Sigma Investments, LP
0.04%
UBS Financial Services, Inc.
0.01%
Other
91.36%
Shareholders
Shareholders
Proportion
Nortye International Ltd
7.47%
Nortye Talent Ltd
1.12%
Two Sigma Investments, LP
0.04%
UBS Financial Services, Inc.
0.01%
Other
91.36%
Shareholder Types
Shareholders
Proportion
Corporation
8.59%
Hedge Fund
0.04%
Investment Advisor
0.02%
Other
91.36%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
8
16.26K
0.36%
--
2025Q3
8
16.26K
0.36%
-43.42K
2025Q2
7
59.68K
0.18%
+3.12K
2025Q1
5
56.56K
0.18%
-420.00
2024Q4
4
56.89K
0.20%
-6.80K
2024Q3
4
63.69K
0.19%
+4.64K
2024Q2
4
59.05K
0.20%
-1.37K
2024Q1
4
60.42K
0.20%
-3.15K
2023Q4
4
62.99K
0.15%
+14.74K
2023Q3
3
48.25K
0.00%
+48.25K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nortye International Ltd
2.33M
7.47%
+2.33M
--
Dec 31, 2024
Nortye Talent Ltd
349.27K
1.12%
+349.27K
--
Dec 31, 2024
Two Sigma Investments, LP
37.40K
0.12%
+37.40K
--
Jun 30, 2025
UBS Financial Services, Inc.
5.31K
0.02%
+637.00
+13.63%
Jun 30, 2025
Morgan Stanley & Co. LLC
65.00
0%
+46.00
+242.11%
Jun 30, 2025
Citadel Advisors LLC
16.91K
0.05%
+16.91K
--
Jun 30, 2025
Cantor Fitzgerald, L.P
--
0%
-40.31K
-100.00%
Jun 30, 2025
Millennium Management LLC
--
0%
-11.56K
-100.00%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Adlai Nortye Ltd?
The top five shareholders of Adlai Nortye Ltd are:
Nortye International Ltd holds 2.33M shares, accounting for 7.47% of the total shares.
Nortye Talent Ltd holds 349.27K shares, accounting for 1.12% of the total shares.
Two Sigma Investments, LP holds 37.40K shares, accounting for 0.12% of the total shares.
UBS Financial Services, Inc. holds 5.31K shares, accounting for 0.02% of the total shares.
Morgan Stanley & Co. LLC holds 65.00 shares, accounting for 0.00% of the total shares.
Nortye International Ltd holds 2.33M shares, accounting for 7.47% of the total shares.
Nortye Talent Ltd holds 349.27K shares, accounting for 1.12% of the total shares.
Two Sigma Investments, LP holds 37.40K shares, accounting for 0.12% of the total shares.
UBS Financial Services, Inc. holds 5.31K shares, accounting for 0.02% of the total shares.
Morgan Stanley & Co. LLC holds 65.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Adlai Nortye Ltd?
The top three shareholder types of Adlai Nortye Ltd are:
Nortye International Ltd
Nortye Talent Ltd
Two Sigma Investments, LP
Nortye International Ltd
Nortye Talent Ltd
Two Sigma Investments, LP
How many institutions hold shares of Adlai Nortye Ltd (ANL)?
As of 2025Q4, 8 institutions hold shares of Adlai Nortye Ltd, with a combined market value of approximately 16.26K, accounting for 0.36% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Adlai Nortye Ltd?
In --, the -- business generated the highest revenue for Adlai Nortye Ltd, amounting to -- and accounting for --% of total revenue.
